Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sinopharm vaccine. Photo Illustration: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images
Health regulators in China said Thursday they have approved the country's first homegrown COVID-19 vaccine, developed by the state-owned pharmaceutical company Sinopharm, for general use, AP reports.
Why it matters: Like the vaccine developed by AstraZeneca and Oxford University, Sinopharm's shot is said to be cheaper and easier to store than Pfizer or Moderna's vaccines.
- China, which has suffered global damage to its reputation after its handling of the initial coronavirus outbreak in Wuhan, is eager to distribute the vaccine to poorer countries that have been unable to secure Pfizer or Moderna doses.
- The UAE, Bahrain, Pakistan and Morocco are among those slated to receive Sinopharm doses, while Turkey, Indonesia and Brazil have purchased a vaccine developed by another Chinese company called Sinovac Biotech, per AP.
The state of play: Sinopharm's approval comes just after China started a program to vaccinate 50 million people before the Lunar New Year in February. 4.5 million doses of the shot have already been administered.
Details: Sinopharm announced Wednesday that preliminary data have shown the vaccine to be 79.3% effective, though experts have said important data is missing. The shot is under conditional approval by China, and the publication of more data will determine the proof of its effectiveness.
Go deeper: China's high-stakes vaccine moment